Michaël Desjardins

4.2k total citations
38 papers, 977 citations indexed

About

Michaël Desjardins is a scholar working on Infectious Diseases, Epidemiology and Immunology. According to data from OpenAlex, Michaël Desjardins has authored 38 papers receiving a total of 977 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 14 papers in Epidemiology and 8 papers in Immunology. Recurrent topics in Michaël Desjardins's work include COVID-19 Clinical Research Studies (12 papers), SARS-CoV-2 and COVID-19 Research (11 papers) and Bacterial Infections and Vaccines (6 papers). Michaël Desjardins is often cited by papers focused on COVID-19 Clinical Research Studies (12 papers), SARS-CoV-2 and COVID-19 Research (11 papers) and Bacterial Infections and Vaccines (6 papers). Michaël Desjardins collaborates with scholars based in Canada, United States and Ivory Coast. Michaël Desjardins's co-authors include Caroline Quach, Sanjat Kanjilal, Matthew P. Cheng, Jesse Papenburg, Cédric P. Yansouni, Sabine Dittrich, Michael Libman, Lindsey R. Baden, Amy C Sherman and David R. Walt and has published in prestigious journals such as Annals of Internal Medicine, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Michaël Desjardins

30 papers receiving 955 citations

Peers

Michaël Desjardins

EPIDE

IMMUN

Yunxia Tang China

Guiju Gao China

Duaa W. Al‐Sadeq Qatar

Irene Cassaniti Italy

Mingxia Zhang China

Bingyi Yang Hong Kong

Marcel Andrée Germany

Jenna Schafers United Kingdom

Liting Yan China

Frankie Wai Tsoi Cheng Hong Kong

Yunxia Tang China

Michaël Desjardins

615 ×0.9

120 ×0.9

161 ×1.4

139 ×1.2

EPIDE

88 ×0.8

IMMUN

Citations per year, relative to Michaël Desjardins Michaël Desjardins (= 1×) peers Yunxia Tang

Countries citing papers authored by Michaël Desjardins

Since Specialization

Citations

This map shows the geographic impact of Michaël Desjardins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michaël Desjardins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michaël Desjardins more than expected).

Fields of papers citing papers by Michaël Desjardins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michaël Desjardins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michaël Desjardins. The network helps show where Michaël Desjardins may publish in the future.

Co-authorship network of co-authors of Michaël Desjardins

This figure shows the co-authorship network connecting the top 25 collaborators of Michaël Desjardins. A scholar is included among the top collaborators of Michaël Desjardins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michaël Desjardins. Michaël Desjardins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cheng, Matthew P., Kaiwen Chen, Eric S. Zhou, et al.. (2025). Letermovir treatment for refractory or resistant cytomegalovirus infection or disease or with concurrent organ dysfunction: A phase 2 open label study. Journal of the Association of Medical Microbiology and Infectious Disease Canada. 10(1). 6–14.

Finlay, Jessica & Michaël Desjardins. (2024). ADVANCING GEOGRAPHIES OF AGING AND THE LIFE COURSE. Innovation in Aging. 8(Supplement_1). 648–648.

Deceuninck, Geneviève, Nicholas Brousseau, Brigitte Lefebvre, et al.. (2024). Effectiveness of the ten- and thirteen-valent pneumococcal conjugate vaccines to prevent serotype 19A invasive pneumococcal disease in Quebec, Canada. A Canadian immunization research network (CIRN) study. Vaccine. 42(26). 126379–126379. 1 indexed citations

Benoit, Patrick, Stephanie Wang, Catherine Wang, et al.. (2024). Brainstorm: A case of granulomatous encephalitis. Journal of the Association of Medical Microbiology and Infectious Disease Canada. 9(2). 113–120.

Wals, Philippe De & Michaël Desjardins. (2023). Influenza vaccines may protect against cardiovascular diseases: The evidence is mounting and should be known by the Canadian public health community. Canada Communicable Disease Report. 49(10). 433–438.

Demir, Koray, Michaël Desjardins, Claude Fortin, et al.. (2023). Treatment of severe human mpox virus infection with tecovirimat: A case series. Canada Communicable Disease Report. 49(2/3). 76–80. 3 indexed citations

Deceuninck, Geneviève, Nicholas Brousseau, Brigitte Lefebvre, et al.. (2023). Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada. Vaccine. 41(38). 5486–5489. 10 indexed citations

Lapierre, Alexandra, Guillaume Fontaine, P. Tremblay, Marc‐André Maheu‐Cadotte, & Michaël Desjardins. (2023). La maladie à coronavirus (COVID-19) : portrait des connaissances actuelles. Érudit (Université de Montréal). 1(1). 13–19.

Follmann, Dean, Holly Janes, Olive D. Buhule, et al.. (2022). Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. Annals of Internal Medicine. 175(9). 1258–1265. 69 indexed citations

10.

Aymonnier, Karen, Julie Ng, Laura E. Fredenburgh, et al.. (2022). Inflammasome activation in neutrophils of patients with severe COVID-19. Blood Advances. 6(7). 2001–2013. 63 indexed citations

11.

Côté, Jean, Michaël Desjardins, Jean‐François Cailhier, Patrick Murray, & William Beaubien–Souligny. (2022). Risk of acute kidney injury associated with anti-pseudomonal and anti-MRSA antibiotic strategies in critically ill patients. PLoS ONE. 17(3). e0264281–e0264281. 5 indexed citations

12.

Sherman, Amy C, Michaël Desjardins, & Lindsey R. Baden. (2021). Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection). Clinics in Laboratory Medicine. 42(1). 111–128. 10 indexed citations

13.

Mysore, Vijayashree, Xavier Culleré, Matthew L. Settles, et al.. (2021). Protective heterologous T cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigens. Med. 2(9). 1050–1071.e7. 38 indexed citations

14.

Cheng, Matthew P., Cédric P. Yansouni, Nicole E. Basta, et al.. (2020). Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus 2. Annals of Internal Medicine. 173(6). 450–460. 91 indexed citations

15.

Desjardins, Michaël, et al.. (2019). Multiplex Polymerase Chain Reaction Panel for Suspected Pertussis. The Pediatric Infectious Disease Journal. 38(10). 1015–1019. 1 indexed citations

16.

Desjardins, Michaël, et al.. (2018). Clinical characteristics of pediatric pertussis cases, Quebec 2015–2017. Canada Communicable Disease Report. 44(9). 190–195. 2 indexed citations

17.

Desjardins, Michaël, et al.. (2018). Clinical characteristics of pediatric pertussis cases, Quebec 2015–2017. Canada Communicable Disease Report. 44(9). 190–195. 10 indexed citations

18.

Desjardins, Michaël, Isabelle Boucoiran, Caroline Paquet, et al.. (2017). Impact of Vaccination History on Serological Testing in Pregnant Women. Journal of Obstetrics and Gynaecology Canada. 40(4). 405–409. 2 indexed citations

19.

Desjardins, Michaël, Brigitte Lefebvre, Annie‐Claude Labbé, et al.. (2017). Agar Gradient Diffusion Susceptibility Testing for Neisseria gonorrhoeae: A Reliable Alternative to Agar Dilution?. Open Forum Infectious Diseases. 4(suppl_1). S107–S107. 1 indexed citations

20.

Desjardins, Michaël. (2002). Challenges of the nursing shortage. Implications for the future.. PubMed. 49(2). 47–50.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact